Search for "biaryl" in Full Text gives 138 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2021, 17, 2668–2679, doi:10.3762/bjoc.17.181
Graphical Abstract
Scheme 1: Selected fluorenone-type natural products.
Scheme 2: Overview of published cyclization methodologies for the synthesis of fluorenones starting from func...
Scheme 3: Preliminary considerations for the oxidative cyclization of 2-(aminomethyl)biphenyls to fluorenones....
Scheme 4: Substrate scope and yields for oxidative cyclizations of N-methyl-2-(aminomethyl)biphenyls 9a–d bea...
Scheme 5: Substrate scope for the oxidative cyclization of 2-(aminomethyl)biphenyls. Conditions: a) Boc2O, NEt...
Scheme 6: Substrate scope for the oxidative cyclization of 2-(aminomethyl)biphenyls with main focus on protec...
Scheme 7: Total synthesis of nobilone (1d). Conditions: a) TBS-Cl, imidazole, DMF, 50 °C, 18 h; b) n-BuLi, B(...
Scheme 8: Proposed mechanism for the oxidative cyclization of amines 2a and 2b to fluorenone (3).
Beilstein J. Org. Chem. 2021, 17, 2543–2552, doi:10.3762/bjoc.17.170
Graphical Abstract
Figure 1: Examples of 2,3-dihydro-1H-pyrrolizines (1–7) and 5,6,7,8-tetrahydroindolizines (8–10).
Scheme 1: Previous [18] and proposed routes to 2,3-dihydro-1H-pyrrolizines from enaminones. Reagents and conditio...
Scheme 2: Synthesis of pyrrolizine 19a from lactam 16 via enaminone 15a. Reagents and conditions: (i) NaH, TH...
Scheme 3: Proposed mechanism for the formation of pyrrolizidine 19a from enaminone (E)-15a.
Scheme 4: Synthesis of tetrahydroindolizines 26a–c from lactam 23 via enaminones 25a–c. Reagents and conditio...
Scheme 5: Further functionalization of dihydropyrrolizine 19a. Reagents and conditions: (i) NBS, DMF, 0 °C, 1...
Beilstein J. Org. Chem. 2021, 17, 2340–2347, doi:10.3762/bjoc.17.152
Graphical Abstract
Figure 1: Biologically active phenanthridines.
Figure 2: Synthetic routes to phenanthridines via iminyl radicals.
Scheme 1: Previous unexpected synthesis of the phenanthridine framework.
Scheme 2: Synthesis of biaryl benzaldehydes.
Scheme 3: Synthesis of biaryl oximes.
Scheme 4: Synthesis of phenanthridines. Reagents and conditions (i) UV irradiation (450 W medium pressure Hg ...
Figure 3: Two possible mechanistic routes and intermediates in the synthesis of phenanthridines.
Scheme 5: Synthesis of trisphaeridine. Reagents and conditions (i) cat. Pd(PPh3)4, aq Na2CO3, DME, reflux, Ar...
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Beilstein J. Org. Chem. 2021, 17, 991–1000, doi:10.3762/bjoc.17.81
Graphical Abstract
Figure 1: Structures and numbering of berberine (1a), berberrubine (1b) and 9-O-aryl-substituted berberine de...
Scheme 1: Synthesis of 10-O-arylated berberine derivatives 5a–e.
Scheme 2: Cu2+-catalyzed demethylation of berberrubine (1b).
Figure 2: Temperature dependent emission spectra of derivatives 5a and 5d (c = 10 µM, with 0.25% v/v DMSO) in...
Figure 3: Photometric titration of 5a (A) and 5d (B) (cLigand = 20 μM) with ct DNA (1) in BPE buffer (cNa+ = ...
Figure 4: Fluorimetric titration of 5a (A) and 5d (B, cLigand = 20 μM) with ct DNA (1) in BPE buffer (cNa+ = ...
Figure 5: CD and LD spectra of ct DNA (1 and 2, cDNA = 20 μM; in BPE buffer: 10 mM, pH 7.0; with 5% v/v DMSO)...
Beilstein J. Org. Chem. 2021, 17, 819–865, doi:10.3762/bjoc.17.71
Graphical Abstract
Figure 1: Marketed drugs with acridine moiety.
Scheme 1: Synthesis of 4-arylacridinediones.
Scheme 2: Proposed mechanism for acridinedione synthesis.
Scheme 3: Synthesis of tetrahydrodibenzoacridinones.
Scheme 4: Synthesis of naphthoacridines.
Scheme 5: Plausible mechanism for naphthoacridines.
Figure 2: Benzoazepines based potent molecules.
Scheme 6: Synthesis of azepinone.
Scheme 7: Proposed mechanism for azepinone formation.
Scheme 8: Synthesis of benzoazulenen-1-one derivatives.
Scheme 9: Proposed mechanism for benzoazulene-1-one synthesis.
Figure 3: Indole-containing pharmacologically active molecules.
Scheme 10: Synthesis of functionalized indoles.
Scheme 11: Plausible mechanism for the synthesis of functionalized indoles.
Scheme 12: Synthesis of spirooxindoles.
Scheme 13: Synthesis of substituted spirooxindoles.
Scheme 14: Plausible mechanism for the synthesis of substituted spirooxindoles.
Scheme 15: Synthesis of pyrrolidinyl spirooxindoles.
Scheme 16: Proposed mechanism for pyrrolidinyl spirooxindoles.
Figure 4: Pyran-containing biologically active molecules.
Scheme 17: Synthesis of functionalized benzopyrans.
Scheme 18: Plausible mechanism for synthesis of benzopyran.
Scheme 19: Synthesis of indoline-spiro-fused pyran derivatives.
Scheme 20: Proposed mechanism for indoline-spiro-fused pyran.
Scheme 21: Synthesis of substituted naphthopyrans.
Figure 5: Marketed drugs with pyrrole ring.
Scheme 22: Synthesis of tetra-substituted pyrroles.
Scheme 23: Mechanism for silica-supported PPA-SiO2-catalyzed pyrrole synthesis.
Scheme 24: Synthesis of pyrrolo[1,10]-phenanthrolines.
Scheme 25: Proposed mechanism for pyrrolo[1,10]-phenanthrolines.
Figure 6: Marketed drugs and molecules containing pyrimidine and pyrimidinones skeletons.
Scheme 26: MWA-MCR pyrimidinone synthesis.
Scheme 27: Two proposed mechanisms for pyrimidinone synthesis.
Scheme 28: MWA multicomponent synthesis of dihydropyrimidinones.
Scheme 29: Proposed mechanism for dihydropyrimidinones.
Figure 7: Biologically active fused pyrimidines.
Scheme 30: MWA- MCR for the synthesis of pyrrolo[2,3-d]pyrimidines.
Scheme 31: Proposed mechanism for pyrrolo[2,3-d]pyrimidines.
Scheme 32: Synthesis of substituted pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 33: Probable pathway for pyrrolo[2,3-d]pyrimidine-2,4-diones.
Scheme 34: Synthesis of pyridopyrimidines.
Scheme 35: Plausible mechanism for the synthesis of pyridopyrimidines.
Scheme 36: Synthesis of dihydropyridopyrimidine and dihydropyrazolopyridine.
Scheme 37: Proposed mechanism for the formation of dihydropyridopyrimidine.
Scheme 38: Synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 39: Plausible mechanism for the synthesis of thiopyrano[4,3-d]pyrimidines.
Scheme 40: Synthesis of decorated imidazopyrimidines.
Scheme 41: Proposed mechanism for imidazopyrimidine synthesis.
Figure 8: Pharmacologically active molecules containing purine bases.
Scheme 42: Synthesis of aza-adenines.
Scheme 43: Synthesis of 5-aza-7-deazapurines.
Scheme 44: Proposed mechanism for deazapurines synthesis.
Figure 9: Biologically active molecules containing pyridine moiety.
Scheme 45: Synthesis of steroidal pyridines.
Scheme 46: Proposed mechanism for steroidal pyridine.
Scheme 47: Synthesis of N-alkylated 2-pyridones.
Scheme 48: Two possible mechanisms for pyridone synthesis.
Scheme 49: Synthesis of pyridone derivatives.
Scheme 50: Postulated mechanism for synthesis of pyridone.
Figure 10: Biologically active fused pyridines.
Scheme 51: Benzimidazole-imidazo[1,2-a]pyridines synthesis.
Scheme 52: Mechanism for the synthesis of benzimidazole-imidazo[1,2-a]pyridines.
Scheme 53: Synthesis of pyrazolo[3,4-b]pyridine-5-spirocycloalkanedione derivatives.
Scheme 54: Proposed mechanism for spiro-pyridines.
Scheme 55: Functionalized macrocyclane-fused pyrazolo[3,4-b]pyridine derivatives.
Scheme 56: Mechanism postulated for macrocyclane-fused pyrazolo[3,4-b]pyridine.
Scheme 57: Generation of pyrazolo[3,4-b]pyridines.
Scheme 58: Proposed mechanism for the synthesis of pyrazolo[3,4-b]pyridines.
Scheme 59: Proposed mechanism for the synthesis of azepinoindole.
Figure 11: Pharmaceutically important molecules with quinoline moiety.
Scheme 60: Povarov-mediated quinoline synthesis.
Scheme 61: Proposed mechanism for Povarov reaction.
Scheme 62: Synthesis of pyrazoloquinoline.
Scheme 63: Plausible mechanism for pyrazoloquinoline synthesis.
Figure 12: Quinazolinones as pharmacologically significant scaffolds.
Scheme 64: Four-component reaction for dihydroquinazolinone.
Scheme 65: Proposed mechanism for dihydroquinazolinones.
Scheme 66: Synthesis purine quinazolinone and PI3K-δ inhibitor.
Scheme 67: Synthesis of fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 68: Proposed mechanism for fused benzothiazolo/benzoimidazoloquinazolinones.
Scheme 69: On-water reaction for synthesis of thiazoloquinazolinone.
Scheme 70: Proposed mechanism for the thiazoloquinazolinone synthesis.
Scheme 71: β-Cyclodextrin-mediated synthesis of indoloquinazolinediones.
Scheme 72: Proposed mechanism for synthesis of indoloquinazolinediones.
Figure 13: Triazoles-containing marketted drugs and pharmacologically active molecules.
Scheme 73: Cu(I) DAPTA-catalyzed 1,2,3-triazole formation.
Scheme 74: Mechanism for Cu(I) DAPTA-catalyzed triazole formation.
Scheme 75: Synthesis of β-hydroxy-1,2,3-triazole.
Scheme 76: Proposed mechanism for synthesis of β-hydroxy-1,2,3-triazoles.
Scheme 77: Synthesis of bis-1,2,4-triazoles.
Scheme 78: Proposed mechanism for bis-1,2,4-triazoles synthesis.
Figure 14: Thiazole containing drugs.
Scheme 79: Synthesis of a substituted thiazole ring.
Scheme 80: Synthesis of pyrazolothiazoles.
Figure 15: Chromene containing drugs.
Scheme 81: Magnetic nanocatalyst-mediated aminochromene synthesis.
Scheme 82: Proposed mechanism for the synthesis of chromenes.
Beilstein J. Org. Chem. 2021, 17, 396–403, doi:10.3762/bjoc.17.35
Graphical Abstract
Scheme 1: Conventional methods for the synthesis of helicenes.
Scheme 2: Brønsted acid-catalyzed cycloaromatization of biaryls bearing an acetal moiety.
Scheme 3: Two strategies for the helicene synthesis via Suzuki–Miyaura coupling/cycloaromatization sequence.
Scheme 4: Synthesis of (a) [5]helicene and (b) [6]helicene.
Scheme 5: Synthesis of helicenes with double helical structures.
Scheme 6: Synthesis of hetero[4]-, [5]-, and [6]helicenes.
Beilstein J. Org. Chem. 2021, 17, 343–378, doi:10.3762/bjoc.17.32
Graphical Abstract
Figure 1: Stabilizing interaction in the CF3CH2+ carbenium ion (top) and structure of the first observable fl...
Scheme 1: Isodesmic equations accounting for the destabilizing effect of the CF3 group. ΔE in kcal⋅mol−1, cal...
Scheme 2: Stabilizing effect of fluorine atoms by resonance electron donation in carbenium ions (δ in ppm).
Scheme 3: Direct in situ NMR observation of α-(trifluoromethyl)carbenium ion or protonated alcohols. Δδ = δ19...
Scheme 4: Reported 13C NMR chemical shifts for the α-(trifluoromethyl)carbenium ion 10c (δ in ppm).
Scheme 5: Direct NMR observation of α-(trifluoromethyl)carbenium ions in situ (δ in ppm).
Scheme 6: Illustration of the ion pair solvolysis mechanism for sulfonate 13f. YOH = solvent.
Figure 2: Solvolysis rate for 13a–i and 17.
Figure 3: Structures of allyl triflates 18 and 19 and allyl brosylate 20. Bs = p-BrC6H4SO2.
Figure 4: Structure of tosylate derivatives 21.
Figure 5: a) Structure of triflate derivatives 22. b) Stereochemistry outcomes of the reaction starting from (...
Scheme 7: Solvolysis reaction of naphthalene and anthracenyl derivatives 26 and 29.
Figure 6: Structure of bisarylated derivatives 34.
Figure 7: Structure of bisarylated derivatives 36.
Scheme 8: Reactivity of 9c in the presence of a Brønsted acid.
Scheme 9: Cationic electrocyclization of 38a–c under strongly acidic conditions.
Scheme 10: Brønsted acid-catalyzed synthesis of indenes 42 and indanes 43.
Scheme 11: Reactivity of sulfurane 44 in triflic acid.
Scheme 12: Solvolysis of triflate 45f in alcoholic solvents.
Scheme 13: Synthesis of labeled 18O-52.
Scheme 14: Reactivity of sulfurane 53 in triflic acid.
Figure 8: Structure of tosylates 56 and 21f.
Scheme 15: Resonance forms in benzylic carbenium ions.
Figure 9: Structure of pyrrole derivatives 58 and 59.
Scheme 16: Resonance structure 60↔60’.
Scheme 17: Ga(OTf)3-catalyzed synthesis of 3,3’- and 3,6’-bis(indolyl)methane from trifluoromethylated 3-indol...
Scheme 18: Proposed reaction mechanism.
Scheme 19: Metal-free 1,2-phosphorylation of 3-indolylmethanols.
Scheme 20: Superacid-mediated arylation of thiophene derivatives.
Scheme 21: In situ mechanistic NMR investigations.
Scheme 22: Proposed mechanisms for the prenyltransferase-catalyzed condensation.
Scheme 23: Influence of a CF3 group on the allylic SN1- and SN2-mechanism-based reactions.
Scheme 24: Influence of the CF3 group on the condensation reaction.
Scheme 25: Solvolysis of 90 in TFE.
Scheme 26: Solvolysis of allyl triflates 94 and 97 and isomerization attempt of 96.
Scheme 27: Proposed mechanism for the formation of 95.
Scheme 28: Formation of α-(trifluoromethyl)allylcarbenium ion 100 in a superacid.
Scheme 29: Lewis acid activation of CF3-substituted allylic alcohols.
Scheme 30: Bimetallic-cluster-stabilized α-(trifluoromethyl)carbenium ions.
Scheme 31: Reactivity of cluster-stabilized α-(trifluoromethyl)carbenium ions.
Scheme 32: α-(Trifluoromethyl)propargylium ion 122↔122’ generated from silyl ether 120 in a superacid.
Scheme 33: Formation of α-(trifluoromethyl)propargylium ions from CF3-substituted propargyl alcohols.
Scheme 34: Direct NMR observation of the protonation of some trifluoromethyl ketones in situ and the correspon...
Scheme 35: Selected resonance forms in protonated fluoroketone derivatives.
Scheme 36: Acid-catalyzed Friedel–Crafts reactions of trifluoromethyl ketones 143a,b and 147a–c.
Scheme 37: Enantioselective hydroarylation of CF3-substituted ketones.
Scheme 38: Acid-catalyzed arylation of ketones 152a–c.
Scheme 39: Reactivity of 156 in a superacid.
Scheme 40: Reactivity of α-CF3-substituted heteroaromatic ketones and alcohols as well as 1,3-diketones.
Scheme 41: Reactivity of 168 with benzene in the presence of a Lewis or Brønsted acid.
Scheme 42: Acid-catalyzed three-component asymmetric reaction.
Scheme 43: Anodic oxidation of amines 178a–c and proposed mechanism.
Scheme 44: Reactivity of 179b in the presence of a strong Lewis acid.
Scheme 45: Trifluoromethylated derivatives as precursors of trifluoromethylated iminium ions.
Scheme 46: Mannich reaction with trifluoromethylated hemiaminal 189.
Scheme 47: Suitable nucleophiles reacting with 192 after Lewis acid activation.
Scheme 48: Strecker reaction involving the trifluoromethylated iminium ion 187.
Scheme 49: Reactivity of 199 toward nucleophiles.
Scheme 50: Reactivity of 204a with benzene in the presence of a Lewis acid.
Scheme 51: Reactivity of α-(trifluoromethyl)-α-chloro sulfides in the presence of strong Lewis acids.
Scheme 52: Anodic oxidation of sulfides 213a–h and Pummerer rearrangement.
Scheme 53: Mechanism for the electrochemical oxidation of the sulfide 213a.
Scheme 54: Reactivity of (trifluoromethyl)diazomethane (217a) in HSO3F.
Figure 10: a) Structure of diazoalkanes 217a–c and b) rate-limiting steps of their decomposition.
Scheme 55: Deamination reaction of racemic 221 and enantioenriched (S)-221.
Scheme 56: Deamination reaction of labeled 221-d2. Elimination products were formed in this reaction, the yiel...
Scheme 57: Deamination reaction of 225-d2. Elimination products were also formed in this reaction in undetermi...
Scheme 58: Formation of 229 from 228 via 1,2-H-shift.
Scheme 59: Deamination reaction of 230. Elimination products were formed in this reaction, the yield of which ...
Scheme 60: Deamination of several diazonium ions. Elimination products were formed in these reactions, the yie...
Scheme 61: Solvolysis reaction mechanism of alkyl tosylates.
Scheme 62: Solvolysis outcome for the tosylates 248 and 249 in HSO3FSbF5.
Figure 11: Solvolysis rate of 248, 249, 252, and 253 in 91% H2SO4.
Scheme 63: Illustration of the reaction pathways. TsCl, pyridine, −5 °C (A); 98% H2SO4, 30 °C (B); 98% H2SO4, ...
Scheme 64: Proposed solvolysis mechanism for the aliphatic tosylate 248.
Scheme 65: Solvolysis of the derivatives 259 and 260.
Scheme 66: Solvolysis of triflate 261. SOH = solvent.
Scheme 67: Intramolecular Friedel–Crafts alkylations upon the solvolysis of triflates 264 and 267.
Scheme 68: α-CF3-enhanced γ-silyl elimination of cyclobutyltosylates 270a,b.
Scheme 69: γ-Silyl elimination in the synthesis of a large variety of CF3-substituted cyclopropanes. Pf = pent...
Scheme 70: Synthetic pathways to 281. aNMR yields.
Scheme 71: The cyclopropyl-substituted homoallylcyclobutylcarbenium ion manifold.
Scheme 72: Reactivity of CF3-substituted cyclopropylcarbinyl derivatives 287a–c. LG = leaving group.
Scheme 73: Reactivity of CF3-substituted cyclopropylcarbinyl derivatives 291a–c.
Scheme 74: Superacid-promoted dimerization or TFP.
Scheme 75: Reactivity of TFP in a superacid.
Scheme 76: gem-Difluorination of α-fluoroalkyl styrenes via the formation of a “hidden” α-RF-substituted carbe...
Scheme 77: Solvolysis of CF3-substituted pentyne 307.
Scheme 78: Photochemical rearrangement of 313.
Figure 12: Structure of 2-norbornylcarbenium ion 318 and argued model for the stabilization of this cation.
Figure 13: Structures and solvolysis rate (TFE, 25 °C) of the sulfonates 319–321. Mos = p-MeOC6H4SO2.
Scheme 79: Mechanism for the solvolysis of 323. SOH = solvent.
Scheme 80: Products formed by the hydrolysis of 328.
Scheme 81: Proposed carbenium ion intermediates in an equilibrium during the solvolysis of tosylates 328, 333,...
Beilstein J. Org. Chem. 2021, 17, 224–228, doi:10.3762/bjoc.17.22
Graphical Abstract
Scheme 1: Biphenyl-derived mycotoxins.
Scheme 2: Synthesis of arylboronates 6. Conditions: a) TBSCl, DMAP, imidazole, DMF, 50 °C, 4 h (96%); b) NBS,...
Scheme 3: Synthesis of aryl bromides 9. Conditions: f) BBr3, −78 °C to rt, 18 h (71%); g) R = TBS: TBSCl, DMA...
Scheme 4: Final steps in the synthesis of biaryl 1. Conditions: h) Pd(OAc)2, SPhos, Cs2CO3, dioxane/H2O 7:1, ...
Beilstein J. Org. Chem. 2020, 16, 3008–3014, doi:10.3762/bjoc.16.250
Graphical Abstract
Scheme 1: Synthesis of biarenes via a) photogenerated triplet aryl cations and aryl radicals (PC = photocatal...
Scheme 2: Metal-free photochemical synthesis of biaryls 2 and 4.
Figure 1: Emission spectrum of compound 1e (red) and of diethyl p-tert-butylphenyl phosphate (black) in metha...
Figure 2: Emission spectrum of compound 1h (red) and of diethyl p-cyanophenyl phosphate (black) in methanol.
Figure 3: Emission spectrum of compound 3a in methanol (black) and in a methanol/TFE 4:1 mixture (red).
Figure 4: Emission spectrum of 3c in MeOH (dotted line) and in the presence of increasing amounts of TFE (up ...
Scheme 3: Photoreactivity of aryl phosphates 1 and 3 in protic media.
Beilstein J. Org. Chem. 2020, 16, 2026–2031, doi:10.3762/bjoc.16.169
Graphical Abstract
Figure 1: Selected natural products synthesized via oxidative dimerization.
Scheme 1: Proposed biosynthesis of balsaminone A (4) [19].
Scheme 2: Proposed biosynthesis of ellagic acid (5) [20].
Scheme 3: Previous syntheses of balsaminone A (4) [22] and ellagic acid (5) [23].
Scheme 4: Attempted synthesis of the biomimetic precursor 9. [O]: Act-C, K3[Fe(CN)6], or p-benzoquinone.
Scheme 5: Biomimetic synthesis of balsaminone A (4).
Scheme 6: Concise and efficient biomimetic synthesis of ellagic acid (5).
Beilstein J. Org. Chem. 2020, 16, 1754–1804, doi:10.3762/bjoc.16.147
Graphical Abstract
Figure 1: Concept of dual synergistic catalysis.
Figure 2: Classification of catalytic systems involving two catalysts.
Figure 3: General mechanism for the dual nickel/photoredox catalytic system.
Figure 4: General mechanisms for C–H activation catalysis involving different reoxidation strategies.
Figure 5: Indole synthesis via dual C–H activation/photoredox catalysis.
Figure 6: Proposed mechanism for the indole synthesis via dual catalysis.
Figure 7: Oxidative Heck reaction on arenes via the dual catalysis.
Figure 8: Proposed mechanism for the Heck reaction on arenes via dual catalysis.
Figure 9: Oxidative Heck reaction on phenols via the dual catalysis.
Figure 10: Proposed mechanism for the Heck reaction on phenols via dual catalysis.
Figure 11: Carbazole synthesis via dual C–H activation/photoredox catalysis.
Figure 12: Proposed mechanism for the carbazole synthesis via dual catalysis.
Figure 13: Carbonylation of enamides via the dual C–H activation/photoredox catalysis.
Figure 14: Proposed mechanism for carbonylation of enamides via dual catalysis.
Figure 15: Annulation of benzamides via the dual C–H activation/photoredox catalysis.
Figure 16: Proposed mechanism for the annulation of benzamides via dual catalysis.
Figure 17: Synthesis of indoles via the dual C–H activation/photoredox catalysis.
Figure 18: Proposed mechanism for the indole synthesis via dual catalysis.
Figure 19: General concept of dual catalysis merging C–H activation and photoredox catalysis.
Figure 20: The first example of dual catalysis merging C–H activation and photoredox catalysis.
Figure 21: Proposed mechanism for the C–H arylation with diazonium salts via dual catalysis.
Figure 22: Dual catalysis merging C–H activation/photoredox using diaryliodonium salts.
Figure 23: Direct arylation via the dual catalytic system reported by Xu.
Figure 24: Direct arylation via dual catalytic system reported by Balaraman.
Figure 25: Direct arylation via dual catalytic system reported by Guo.
Figure 26: C(sp3)–H bond arylation via the dual Pd/photoredox catalytic system.
Figure 27: Acetanilide derivatives acylation via the dual C–H activation/photoredox catalysis.
Figure 28: Proposed mechanism for the C–H acylation with α-ketoacids via dual catalysis.
Figure 29: Acylation of azobenzenes via the dual catalysis C–H activation/photoredox.
Figure 30: C2-acylation of indoles via the dual C–H activation/photoredox catalysis.
Figure 31: Proposed mechanism for the C2-acylation of indoles with aldehydes via dual catalysis.
Figure 32: C2-acylation of indoles via the dual C–H activation/photoredox catalysis.
Figure 33: Perfluoroalkylation of arenes via the dual C–H activation/photoredox catalysis.
Figure 34: Proposed mechanism for perfluoroalkylation of arenes via dual catalysis.
Figure 35: Sulfonylation of 1-naphthylamides via the dual C–H activation/photoredox catalysis.
Figure 36: Proposed mechanism for sulfonylation of 1-naphthylamides via dual catalysis.
Figure 37: meta-C–H Alkylation of arenes via visible-light metallaphotocatalysis.
Figure 38: Alternative procedure for meta-C–H alkylation of arenes via metallaphotocatalysis.
Figure 39: Proposed mechanism for meta-C–H alkylation of arenes via metallaphotocatalysis.
Figure 40: C–H borylation of arenes via visible-light metallaphotocatalysis.
Figure 41: Proposed mechanism for C–H borylation of arenes via visible-light metallaphotocatalysis.
Figure 42: Undirected C–H aryl–aryl cross coupling via dual gold/photoredox catalysis.
Figure 43: Proposed mechanism for the undirected C–H aryl–aryl cross-coupling via dual catalysis.
Figure 44: Undirected C–H arylation of (hetero)arenes via dual manganese/photoredox catalysis.
Figure 45: Proposed mechanism for the undirected arylation of (hetero)arenes via dual catalysis.
Figure 46: Photoinduced C–H arylation of azoles via copper catalysis.
Figure 47: Photo-induced C–H chalcogenation of azoles via copper catalysis.
Figure 48: Decarboxylative C–H adamantylation of azoles via dual cobalt/photoredox catalysis.
Figure 49: Proposed mechanism for the C–H adamantylation of azoles via dual catalysis.
Figure 50: General mechanisms for the “classical” (left) and Cu-free variant (right) Sonogoshira reaction.
Figure 51: First example of a dual palladium/photoredox catalysis for Sonogashira-type couplings.
Figure 52: Arylation of terminal alkynes with diazonium salts via dual gold/photoredox catalysis.
Figure 53: Proposed mechanism for the arylation of terminal alkynes via dual catalysis.
Figure 54: C–H Alkylation of alcohols promoted by H-atom transfer (HAT).
Figure 55: Proposed mechanism for the C–H alkylation of alcohols promoted by HAT.
Figure 56: C(sp3)–H arylation of latent nucleophiles promoted by H-atom transfer.
Figure 57: Proposed mechanism for the C(sp3)–H arylation of latent nucleophiles promoted by HAT.
Figure 58: Direct α-arylation of alcohols promoted by H-atom transfer.
Figure 59: Proposed mechanism for the direct α-arylation of alcohols promoted by HAT.
Figure 60: C–H arylation of amines via dual Ni/photoredox catalysis.
Figure 61: Proposed mechanism for the C–H arylation of amines via dual Ni/photoredox catalysis.
Figure 62: C–H functionalization of nucleophiles via excited ketone/nickel dual catalysis.
Figure 63: Proposed mechanism for the C–H functionalization enabled by excited ketones.
Figure 64: Selective sp3–sp3 cross-coupling promoted by H-atom transfer.
Figure 65: Proposed mechanism for the selective sp3–sp3 cross-coupling promoted by HAT.
Figure 66: Direct C(sp3)–H acylation of amines via dual Ni/photoredox catalysis.
Figure 67: Proposed mechanism for the C–H acylation of amines via dual Ni/photoredox catalysis.
Figure 68: C–H hydroalkylation of internal alkynes via dual Ni/photoredox catalysis.
Figure 69: Proposed mechanism for the C–H hydroalkylation of internal alkynes.
Figure 70: Alternative procedure for the C–H hydroalkylation of ynones, ynoates, and ynamides.
Figure 71: Allylic C(sp3)–H activation via dual Ni/photoredox catalysis.
Figure 72: Proposed mechanism for the allylic C(sp3)–H activation via dual Ni/photoredox catalysis.
Figure 73: Asymmetric allylation of aldehydes via dual Cr/photoredox catalysis.
Figure 74: Proposed mechanism for the asymmetric allylation of aldehydes via dual catalysis.
Figure 75: Aldehyde C–H functionalization promoted by H-atom transfer.
Figure 76: Proposed mechanism for the C–H functionalization of aldehydes promoted by HAT.
Figure 77: Direct C–H arylation of strong aliphatic bonds promoted by HAT.
Figure 78: Proposed mechanism for the C–H arylation of strong aliphatic bonds promoted by HAT.
Figure 79: Direct C–H trifluoromethylation of strong aliphatic bonds promoted by HAT.
Figure 80: Proposed mechanism for the C–H trifluoromethylation of strong aliphatic bonds.
Beilstein J. Org. Chem. 2020, 16, 1476–1488, doi:10.3762/bjoc.16.123
Graphical Abstract
Figure 1: Bioactive phenanthridine and phenanthridinium derivatives.
Scheme 1: Synthesis of phenanthrenes by a photo-Pschorr reaction.
Scheme 2: Synthesis of phenanthrenes by a benzannulation reaction.
Scheme 3: Photocatalytic cyclization of α-bromochalcones for the synthesis of phenanthrenes.
Figure 2: Carbon-centered and nitrogen-centered radicals used for the synthesis of phenanthridines.
Scheme 4: General scheme describing the synthesis of phenanthridines from isocyanides via imidoyl radicals.
Scheme 5: Synthesis of substituted phenanthridines involving the intermediacy of electrophilic radicals.
Scheme 6: Photocatalyzed synthesis of 6-β-ketoalkyl phenanthridines.
Scheme 7: Synthesis of 6-substituted phenanthridines through the addition of trifluoromethyl (path a), phenyl...
Scheme 8: Synthesis of 6-(trifluoromethyl)-7,8-dihydrobenzo[k]phenanthridine.
Scheme 9: Phenanthridine syntheses by using photogenerated radicals formed through a C–H bond homolytic cleav...
Scheme 10: Trifluoroacetimidoyl chlorides as starting substrates for the synthesis of 6-(trifluoromethyl)phena...
Scheme 11: Synthesis of phenanthridines via aryl–aryl-bond formation.
Scheme 12: Oxidative conversion of N-biarylglycine esters to phenanthridine-6-carboxylates.
Scheme 13: Photocatalytic synthesis of benzo[f]quinolines from 2-heteroaryl-substituted anilines and heteroary...
Scheme 14: Synthesis of noravicine (14.2a) and nornitidine (14.2b) alkaloids.
Scheme 15: Gram-scale synthesis of the alkaloid trisphaeridine (15.3).
Scheme 16: Synthesis of phenanthridines starting from vinyl azides.
Scheme 17: Synthesis of pyrido[4,3,2-gh]phenanthridines 17.5a–d through the radical trifluoromethylthiolation ...
Scheme 18: The direct oxidative C–H amidation involving amidyl radicals for the synthesis of phenanthridones.
Beilstein J. Org. Chem. 2020, 16, 1234–1276, doi:10.3762/bjoc.16.107
Graphical Abstract
Figure 1: Imine-N-oxyl radicals (IV) discussed in the present review and other classes of N-oxyl radicals (I–...
Figure 2: The products of decomposition of iminoxyl radicals generated from oximes by oxidation with Ag2O.
Scheme 1: Generation of oxime radicals and study of the kinetics of their decay by photolysis of the solution...
Scheme 2: Synthesis of di-tert-butyliminoxyl radical and its decomposition products.
Scheme 3: The proposed reaction pathway of the decomposition of di-tert-butyliminoxyl radical (experimentally...
Scheme 4: Monomolecular decomposition of the tert-butyl(triethylmethyl)oxime radical.
Scheme 5: The synthesis and stability of the most stable dialkyl oxime radicals – di-tert-butyliminoxyl and d...
Scheme 6: The formation of iminoxyl radicals from β-diketones under the action of NO2.
Scheme 7: Synthesis of the diacetyliminoxyl radical.
Scheme 8: Examples of long-living oxime radicals with electron-withdrawing groups and the conditions for thei...
Figure 3: The electronic structure iminoxyl radicals and their geometry compared to the corresponding oximes.
Figure 4: Bond dissociation enthalpies (kcal/mol) of oximes and N,N-disubstituted hydroxylamines calculated o...
Scheme 9: Examples demonstrating the low reactivity of the di-tert-butyliminoxyl radical towards the substrat...
Scheme 10: The reactions of di-tert-butyliminoxyl radical with unsaturated hydrocarbons involving hydrogen ato...
Scheme 11: Possible mechanisms of reaction of di-tert-butyliminoxyl radical with alkenes.
Scheme 12: Products of the reaction between di-tert-butyliminoxyl radical and phenol derivatives.
Scheme 13: The reaction of di-tert-butyliminoxyl radical with amines.
Scheme 14: Reaction of di-tert-butyliminoxyl radicals with organolithium reagents.
Scheme 15: Cross-dehydrogenative C–O coupling of 1,3-dicarbonyl compounds with oximes under the action of mang...
Scheme 16: Cross-dehydrogenative C–O coupling of 1,3-dicarbonyl compounds with oximes under the action of Cu(BF...
Scheme 17: Oxidative C–O coupling of benzylmalononitrile (47) with 3-(hydroxyimino)pentane-2,4-dione (19).
Scheme 18: The proposed mechanism of the oxidative coupling of benzylmalononitrile (47) with diacetyl oxime (19...
Scheme 19: Oxidative C–O coupling of pyrazolones with oximes under the action of Fe(ClO4)3.
Scheme 20: The reaction of diacetyliminoxyl radical with pyrazolones.
Scheme 21: Oxidative C–O coupling of oximes with acetonitrile, ketones, and esters.
Scheme 22: Intramolecular cyclizations of oxime radicals to form substituted isoxazolines or cyclic nitrones.
Scheme 23: TEMPO-mediated oxidative cyclization of oximes with C–H bond cleavage.
Scheme 24: Proposed reaction mechanism of oxidative cyclization of oximes with C–H bond cleavage.
Scheme 25: Selectfluor/Bu4NI-mediated C–H oxidative cyclization of oximes.
Scheme 26: Oxidative cyclization of N-benzyl amidoximes to 1,2,4-oxadiazoles.
Scheme 27: The formation of quinazolinone 73a from 5-phenyl-4,5-dihydro-1,2,4-oxadiazole 74 under air.
Scheme 28: DDQ-mediated oxidative cyclization of thiohydroximic acids.
Scheme 29: Plausible mechanism of the oxidative cyclization of thiohydroximic acids.
Scheme 30: Silver-mediated oxidative cyclization of α-halogenated ketoximes and 1,3-dicarbonyl compounds.
Scheme 31: Possible pathway of one-pot oxidative cyclization of α-halogenated ketoximes and 1,3-dicarbonyl com...
Scheme 32: T(p-F)PPT-catalyzed oxidative cyclization of oximes with the formation of 1,2,4-oxadiazolines.
Scheme 33: Intramolecular cyclization of iminoxyl radicals involving multiple C=C and N=N bonds.
Scheme 34: Oxidative cyclization of β,γ- and γ,δ-unsaturated oximes employing the DEAD or TEMPO/DEAD system wi...
Scheme 35: Cobalt-catalyzed aerobic oxidative cyclization of β,γ-unsaturated oximes.
Scheme 36: Manganese-catalyzed aerobic oxidative cyclization of β,γ-unsaturated oximes.
Scheme 37: Visible light photocatalytic oxidative cyclization of β,γ-unsaturated oximes.
Scheme 38: TBAI/TBHP-mediated radical cascade cyclization of the β,γ-unsaturated oximes.
Scheme 39: TBAI/TBHP-mediated radical cascade cyclization of vinyl isocyanides with β,γ-unsaturated oximes.
Scheme 40: tert-Butylnitrite-mediated oxidative cyclization of unsaturated oximes with the introduction of an ...
Scheme 41: Transformation of unsaturated oxime to oxyiminomethylisoxazoline via the confirmed dimeric nitroso ...
Scheme 42: tert-Butylnitrite-mediated oxidative cyclization of unsaturated oximes with the introduction of a n...
Scheme 43: Synthesis of cyano-substituted oxazolines from unsaturated oximes using the TBN/[RuCl2(p-cymene)]2 ...
Scheme 44: Synthesis of trifluoromethylthiolated isoxazolines from unsaturated oximes.
Scheme 45: Copper-сatalyzed oxidative cyclization of β,γ-unsaturated oximes with the introduction of an azido ...
Scheme 46: TBHP-mediated oxidative cascade cyclization of β,γ-unsaturated oximes and unsaturated N-arylamides.
Scheme 47: Copper-сatalyzed oxidative cyclization of unsaturated oximes with the introduction of an amino grou...
Scheme 48: TEMPO-mediated oxidative cyclization of unsaturated oximes followed by elimination.
Scheme 49: Oxidative cyclization of β,γ-unsaturated oximes with the introduction of a trifluoromethyl group.
Scheme 50: Oxidative cyclization of unsaturated oximes with the introduction of a nitrile group.
Scheme 51: Oxidative cyclization of β,γ-unsaturated oximes to isoxazolines with the introduction of a nitrile ...
Scheme 52: Oxidative cyclization of β,γ-unsaturated oximes to isoxazolines with the introduction of a sulfonyl...
Scheme 53: Oxidative cyclization of β,γ- and γ,δ-unsaturated oximes to isoxazolines with the introduction of a...
Scheme 54: Oxidative cyclization of β,γ-unsaturated oximes to isoxazolines with the introduction of a thiocyan...
Scheme 55: PhI(OAc)2-mediated oxidative cyclization of oximes with C–S and C–Se bond formation.
Scheme 56: PhI(OAc)2-mediated oxidative cyclization of unsaturated oximes accompanied by alkoxylation.
Scheme 57: PhI(OAc)2-mediated cyclization of unsaturated oximes to methylisoxazolines.
Scheme 58: Oxidative cyclization-alkynylation of unsaturated oximes.
Scheme 59: TEMPO-mediated oxidative cyclization of C-glycoside ketoximes to C-glycosylmethylisoxazoles.
Scheme 60: Silver-сatalyzed oxidative cyclization of β,γ-unsaturated oximes with formation of fluoroalkyl isox...
Scheme 61: Oxidative cyclization of β,γ-unsaturated oximes with the formation of haloalkyl isoxazolines.
Scheme 62: Cyclization of β,γ-unsaturated oximes into haloalkyl isoxazolines under the action of the halogenat...
Scheme 63: Synthesis of haloalkyl isoxazoles and cyclic nitrones via oxidative cyclization and 1,2-halogen shi...
Scheme 64: Electrochemical oxidative cyclization of diaryl oximes.
Scheme 65: Copper-сatalyzed cyclization and dioxygenation oximes containing a triple C≡C bond.
Scheme 66: Photoredox-catalyzed sulfonylation of β,γ-unsaturated oximes by sulfonyl hydrazides.
Scheme 67: Oxidative cyclization of β,γ-unsaturated oximes with introduction of sulfonate group.
Scheme 68: Ultrasound-promoted oxidative cyclization of β,γ-unsaturated oximes.
Beilstein J. Org. Chem. 2020, 16, 1100–1110, doi:10.3762/bjoc.16.97
Graphical Abstract
Figure 1: Structures of pseudosporamide (1) and pseudosporamicins A–C (2–4).
Figure 2: COSY, key HMBC and ROESY correlations of pseudosporamide (1).
Figure 3: 1H NMR ΔδS−R values for PGME amides 5a and 5b obtained from compound 1.
Figure 4: The opposite axial chirality around the biaryl C-6–C-7'' bond influenced by the C-2 configuration i...
Figure 5: The experimental and calculated ECD spectra in MeCN.
Figure 6: COSY, key HMBC and NOESY correlations of compound 2.
Figure 7: NOESY correlations for the spiroacetal moiety of compound 2.
Figure 8: Selected examples of oligomycin-class metabolites from actinomycetes.
Beilstein J. Org. Chem. 2020, 16, 966–973, doi:10.3762/bjoc.16.85
Graphical Abstract
Figure 1: (R)-MeO-MOP and our ligands.
Scheme 1: Asymmetric Suzuki–Miyaura coupling. Reaction conditions: 1 equiv N-aryl-bromoaryl compounds, 2 equi...
Scheme 2: Asymmetric Suzuki–Miyaura coupling. Reaction conditions: 1 equiv of bromoaryl compounds, 2 equiv of...
Scheme 3: Gram-scale reaction.
Scheme 4: Based on our analysis and speculation, a possible intermediate structure is proposed [65,66].
Scheme 5: Method A for the synthesis of amide substrates.
Scheme 6: Method B for the synthesis of amide substrates.
Beilstein J. Org. Chem. 2020, 16, 551–586, doi:10.3762/bjoc.16.52
Graphical Abstract
Scheme 1: Chemical structure of the catalysts 1a and 1b and their catalytic application in CuAAC reactions.
Scheme 2: Synthetic route to the catalyst 11 and its catalytic application in CuAAC reactions.
Scheme 3: Synthetic route of dendrons, illustrated using G2-AMP 23.
Scheme 4: The catalytic application of CuYAu–Gx-AAA–SBA-15 in a CuAAC reaction.
Scheme 5: Synthetic route to the catalyst 36.
Scheme 6: Application of the catalyst 36 in CuAAC reactions.
Scheme 7: The synthetic route to the catalyst 45 and catalytic application of 45 in “click” reactions.
Scheme 8: Synthetic route to the catalyst 48 and catalytic application of 48 in “click” reactions.
Scheme 9: Synthetic route to the catalyst 58 and catalytic application of 58 in “click” reactions.
Scheme 10: Synthetic route to the catalyst 64 and catalytic application of 64 in “click” reactions.
Scheme 11: Chemical structure of the catalyst 68 and catalytic application of 68 in “click” reactions.
Scheme 12: Chemical structure of the catalyst 69 and catalytic application of 69 in “click” reactions.
Scheme 13: Synthetic route to, and chemical structure of the catalyst 74.
Scheme 14: Application of the cayalyst 74 in “click” reactions.
Scheme 15: Synthetic route to, and chemical structure of the catalyst 78 and catalytic application of 78 in “c...
Scheme 16: Synthetic route to the catalyst 85.
Scheme 17: Application of the catalyst 85 in “click” reactions.
Scheme 18: Synthetic route to the catalyst 87 and catalytic application of 87 in “click” reactions.
Scheme 19: Chemical structure of the catalyst 88 and catalytic application of 88 in “click” reactions.
Scheme 20: Synthetic route to the catalyst 90 and catalytic application of 90 in “click” reactions.
Scheme 21: Synthetic route to the catalyst 96 and catalytic application of 96 in “click” reactions.
Scheme 22: Synthetic route to the catalyst 100 and catalytic application of 100 in “click” reactions.
Scheme 23: Synthetic route to the catalyst 102 and catalytic application of 23 in “click” reactions.
Scheme 24: Synthetic route to the catalysts 108–111.
Scheme 25: Catalytic application of 108–111 in “click” reactions.
Scheme 26: Synthetic route to the catalyst 121 and catalytic application of 121 in “click” reactions.
Scheme 27: Synthetic route to 125 and application of 125 in “click” reactions.
Scheme 28: Synthetic route to the catalyst 131 and catalytic application of 131 in “click” reactions.
Scheme 29: Synthetic route to the catalyst 136.
Scheme 30: Application of the catalyst 136 in “click” reactions.
Scheme 31: Synthetic route to the catalyst 141 and catalytic application of 141 in “click” reactions.
Scheme 32: Synthetic route to the catalyst 144 and catalytic application of 144 in “click” reactions.
Scheme 33: Synthetic route to the catalyst 149 and catalytic application of 149 in “click” reactions.
Scheme 34: Synthetic route to the catalyst 153 and catalytic application of 153 in “click” reactions.
Scheme 35: Synthetic route to the catalyst 155 and catalytic application of 155 in “click” reactions.
Scheme 36: Synthetic route to the catalyst 157 and catalytic application of 157 in “click” reactions.
Scheme 37: Synthetic route to the catalyst 162.
Scheme 38: Application of the catalyst 162 in “click” reactions.
Scheme 39: Synthetic route to the catalyst 167 and catalytic application of 167 in “click” reactions.
Scheme 40: Synthetic route to the catalyst 169 and catalytic application of 169 in “click” reactions.
Scheme 41: Synthetic route to the catalyst 172.
Scheme 42: Application of the catalyst 172 in “click” reactions.
Beilstein J. Org. Chem. 2020, 16, 544–550, doi:10.3762/bjoc.16.51
Graphical Abstract
Scheme 1: Projected synthetic routes for 3,6,13,16-tetrasubstituted tetrabenzo[a,d,j,m]coronenes.
Scheme 2: Reported syntheses of 2,7,12,17-tetrasubstituted tetrabenzo[a,d,j,m]coronenes.
Scheme 3: C–H tetraarylation of anthraquinone (1).
Scheme 4: C–H diarylation of 1,4-diarylanthraquinones 5.
Figure 1: Normalized UV–vis absorption spectra of 7aa, 7bb, and 7ba.
Figure 2: Effects of the concentration and the temperature on the 1H NMR spectra of 7aa.
Beilstein J. Org. Chem. 2020, 16, 530–536, doi:10.3762/bjoc.16.49
Graphical Abstract
Scheme 1: Direct C–H arylation of PAHs.
Scheme 2: Scope of aryliodonium salts. Reaction conditions: 1a (0.2 mmol), 2 (0.3 mmol) in DCE (1 mL) at 70 °...
Scheme 3: Scope of PAHs. Reaction conditions: 1 (0.2 mmol), 2a (0.3 mmol) in DCE (1 mL) at 70 °C under N2 for...
Scheme 4: Proposed catalytic cycle.
Figure 1: a) UV-visible absorption spectra of 4k, 4n and 4o in toluene (1 × 10−5 mol/L). b) Emission spectra ...
Beilstein J. Org. Chem. 2020, 16, 409–414, doi:10.3762/bjoc.16.39
Graphical Abstract
Scheme 1: Synthetic methods of six-membered silacyclic compounds.
Scheme 2: Scope of dihydrosilanes. Conditions: a: conditions B (Table 1, entry 5); b: conditions A (Table 1, entry 3).
Scheme 3: Scope of diaryl ether and diaryl thioether derivatives. Conditions: a: conditions B (Table 1, entry 5); b:...
Scheme 4: Gram-scale Synthesis of 3a.
Scheme 5: Transformation of the amino groups in 3a.
Beilstein J. Org. Chem. 2020, 16, 362–383, doi:10.3762/bjoc.16.35
Graphical Abstract
Scheme 1: Synthesis of pyridylphosphine ligands.
Figure 1: Pyridylphosphine ligands.
Scheme 2: Synthesis of piperidyl- and oxazinylphosphine ligands.
Scheme 3: Synthesis of linear multi-chelate pyridylphosphine ligands.
Scheme 4: Synthesis of chiral acetal pyridylphosphine ligands.
Scheme 5: Synthesis of diphenylphosphine-substituted triazine ligands.
Scheme 6: Synthesis of (pyridine-2-ylmethyl)phosphine ligands.
Scheme 7: Synthesis of diphosphine pyrrole ligands.
Scheme 8: Synthesis of 4,5-diazafluorenylphosphine ligands.
Scheme 9: Synthesis of thioether-containing pyridyldiphosphine ligands starting from ethylene sulfide and dip...
Scheme 10: Synthesis of monoterpene-derived phosphine pyridine ligands.
Scheme 11: Synthesis of N-phenylphosphine-substituted imidazole ligands.
Scheme 12: Synthesis of triazol-4-ylphosphine ligands.
Scheme 13: Synthesis of phosphanyltriazolopyridines and product selectivity depending on the substituents’ eff...
Scheme 14: Synthesis of PTA-phosphine ligands.
Scheme 15: Synthesis of isomeric phosphine dipyrazole ligands by varying the reaction temperature.
Scheme 16: Synthesis of N-tethered phosphine imidazolium ligands (route A) and diphosphine imidazolium ligands...
Scheme 17: Synthesis of {1-[2-(pyridin-2-yl)- (R = CH) and {1-[2-(pyrazin-2-yl)quinazolin-4-yl]naphthalen-2-yl...
Scheme 18: Synthesis of oxazolylindolylphosphine ligands 102.
Scheme 19: Synthesis of pyrrolylphosphine ligands.
Scheme 20: Synthesis of phosphine guanidinium ligands.
Scheme 21: Synthesis of a polydentate aminophosphine ligand.
Scheme 22: Synthesis of quinolylphosphine ligands.
Scheme 23: Synthesis of N-(triazolylmethyl)phosphanamine ligands.
Figure 2: Triazolylphosphanamine ligands synthesized by Wassenaar’s method [22].
Scheme 24: Synthesis of oxazaphosphorines.
Scheme 25: Synthesis of paracyclophane pyridylphosphine ligands.
Scheme 26: Synthesis of triazolylphosphine ligands.
Figure 3: Click-phosphine ligands.
Scheme 27: Ferrocenyl pyridylphosphine imine ligands.
Scheme 28: Synthesis of phosphinooxazolines (PHOX).
Scheme 29: Synthesis of ferrocenylphosphine oxazoles.
Beilstein J. Org. Chem. 2020, 16, 325–336, doi:10.3762/bjoc.16.32
Graphical Abstract
Scheme 1: Synthesis of BBFZPys through the Pd-catalyzed C–H/C–H coupling.
Scheme 2: Synthesis of 3a–c.
Scheme 3: Synthesis of 4a–c through oxidative coupling reaction.
Scheme 4: Synthesis of 6.
Figure 1: Absorption (dotted line) and fluorescence (solid line) spectra of 3, 4, and 6 measured as CHCl3 sol...
Figure 2: CD and CPL spectra of 3 measured as CHCl3 solutions (1.0 × 10−5 M) and in the solid states (dispers...
Figure 3: CD and CPL spectra of 4 and 6 measured as CHCl3 solutions (1.0 × 10−5 M) and in solid states (dispe...
Figure 4: ORTEP drawings of 4b and 4c with 50% thermal probability. Hydrogen atoms and solvent molecules are ...
Figure 5: Intramolecular stacking structures of 4b and 4c.
Beilstein J. Org. Chem. 2020, 16, 248–280, doi:10.3762/bjoc.16.26
Graphical Abstract
Figure 1: List of photoredox catalysts used for C–H bond functionalizations.
Figure 2: List of metal-based photoredox catalysts used in this review article.
Figure 3: Jablonski diagram.
Figure 4: Photoredox catalysis via reductive or oxidative pathways. D = donor, A = acceptor, S = substrate, P...
Figure 5: Schematic representation of the combination of photoredox catalysis and transition metal catalysis.
Scheme 1: Weinreb amide C–H olefination.
Figure 6: Mechanism for the formation of 21 from 19 using photoredox catalyst 11.
Scheme 2: C–H olefination of phenolic ethers.
Scheme 3: Decarboxylative acylation of acetanilides.
Figure 7: Mechanism for the formation of 30 from acetanilide derivatives.
Scheme 4: Synthesis of fluorenone derivatives by intramolecular deoxygenative acylation of biaryl carboxylic ...
Figure 8: Mechanism for the photoredox-catalyzed synthesis of fluorenone derivatives.
Scheme 5: Synthesis of benzothiazoles via aerobic C–H thiolation.
Figure 9: Plausible mechanism for the construction of benzothiazoles from benzothioamides.
Scheme 6: Synthesis of benzothiazoles via oxidant-free C–H thiolation.
Figure 10: Mechanism involved in the synthesis of benzothiazoles via oxidant-free C–H thiolation.
Scheme 7: Synthesis of indoles via C–H cyclization of anilides with alkynes.
Scheme 8: Preparation of 3-trifluoromethylcoumarins via C–H cyclization of arylpropiolate esters.
Figure 11: Mechanistic pathway for the synthesis of coumarin derivatives via C–H cyclization.
Scheme 9: Monobenzoyloxylation without chelation assistance.
Figure 12: Plausible mechanism for the formation of 71 from 70.
Scheme 10: Aryl-substituted arenes prepared by inorganic photoredox catalysis using 12a.
Figure 13: Proposed mechanism for C–H arylations in the presence of 12a and a Pd catalyst.
Scheme 11: Arylation of purines via dual photoredox catalysis.
Scheme 12: Arylation of substituted arenes with an organic photoredox catalyst.
Scheme 13: C–H trifluoromethylation.
Figure 14: Proposed mechanism for the trifluoromethylation of 88.
Scheme 14: Synthesis of benzo-3,4-coumarin derivatives.
Figure 15: Plausible mechanism for the synthesis of substituted coumarins.
Scheme 15: Oxidant-free oxidative phosphonylation.
Figure 16: Mechanism proposed for the phosphonylation reaction of 100.
Scheme 16: Nitration of anilines.
Figure 17: Plausible mechanism for the nitration of aniline derivatives via photoredox catalysis.
Scheme 17: Synthesis of carbazoles via intramolecular amination.
Figure 18: Proposed mechanism for the formation of carbazoles from biaryl derivatives.
Scheme 18: Synthesis of substituted phenols using QuCN.
Figure 19: Mechanism for the synthesis of phenol derivatives with photoredox catalyst 8.
Scheme 19: Synthesis of substituted phenols with DDQ (5).
Figure 20: Possible mechanism for the generation of phenols with the aid of photoredox catalyst 5.
Scheme 20: Aerobic bromination of arenes using an acridinium-based photocatalyst.
Scheme 21: Aerobic bromination of arenes with anthraquinone.
Figure 21: Proposed mechanism for the synthesis of monobrominated compounds.
Scheme 22: Chlorination of benzene derivatives with Mes-Acr-MeClO4 (2).
Figure 22: Mechanism for the synthesis of 131 from 132.
Scheme 23: Chlorination of arenes with 4CzIPN (5a).
Figure 23: Plausible mechanism for the oxidative photocatalytic monochlorination using 5a.
Scheme 24: Monofluorination using QuCN-ClO4 (8).
Scheme 25: Fluorination with fluorine-18.
Scheme 26: Aerobic amination with acridinium catalyst 3a.
Figure 24: Plausible mechanism for the aerobic amination using acridinium catalyst 3a.
Scheme 27: Aerobic aminations with semiconductor photoredox catalyst 18.
Scheme 28: Perfluoroalkylation of arenes.
Scheme 29: Synthesis of benzonitriles in the presence of 3a.
Figure 25: Plausible mechanism for the synthesis of substituted benzonitrile derivatives in the presence of 3a....
Beilstein J. Org. Chem. 2020, 16, 125–134, doi:10.3762/bjoc.16.14
Graphical Abstract
Figure 1: a) The potent tubulin inhibitor colchicine as a lead scaffold led to the development of the HOTub g...
Figure 2: Chemical structures of HITubs. Key variations with respect to HITub-4 are highlighted in dashed box...
Figure 3: Photocharacterisation of HITub-4. a) Photochemical and thermal isomerisation. b) UV–vis spectra aft...
Figure 4: a) Resazurin reduction assay for HITub-4 and nocodazole in HeLa cells (n = 3), demonstrating the di...
Figure 5: Confocal microscopy images of immunofluorescently labelled MT networks after treatment with HITubs ...
Figure 6: Cell cycle analysis of HITub-4-treated cells. a) and b) (Z)-HITub-4 caused significant G2/M arrest ...
Beilstein J. Org. Chem. 2019, 15, 2612–2622, doi:10.3762/bjoc.15.254
Graphical Abstract
Figure 1: Structures of the dyes 16–19.
Scheme 1: Synthesis of the precursors 2, 3, and 5.
Scheme 2: Synthesis of the precursor triflates 8–11.
Scheme 3: Synthesis of 12–15 and the organoboron dyes 16–19.
Figure 2: UV–vis absorption (solid line) and fluorescence (dashed line) spectra of a) 16, b) 17, c) 18, and d...
Scheme 4: Jablonski diagram representing the photophysical processes in the dyes 16–19.
Figure 3: Transient absorption spectrum (600 ns delay) of dye 17 in nitrogen-purged acetonitrile on excitatio...
Figure 4: Fluorescence titrations of the dyes (ca. 4–11 μM) with Bu4NF in acetonitrile. a) 16 (up to 156 equi...